577 related articles for article (PubMed ID: 18655816)
1. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases.
Yamada Y; Harashima H
Adv Drug Deliv Rev; 2008; 60(13-14):1439-62. PubMed ID: 18655816
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial drug delivery and mitochondrial disease therapy--an approach to liposome-based delivery targeted to mitochondria.
Yamada Y; Akita H; Kogure K; Kamiya H; Harashima H
Mitochondrion; 2007; 7(1-2):63-71. PubMed ID: 17296332
[TBL] [Abstract][Full Text] [Related]
3. Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter.
Yamada Y; Harashima H
Biomaterials; 2012 Feb; 33(5):1589-95. PubMed ID: 22105068
[TBL] [Abstract][Full Text] [Related]
4. Targeted drug delivery to mammalian mitochondria in living cells.
Weissig V
Expert Opin Drug Deliv; 2005 Jan; 2(1):89-102. PubMed ID: 16296737
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes.
Yasuzaki Y; Yamada Y; Harashima H
Biochem Biophys Res Commun; 2010 Jun; 397(2):181-6. PubMed ID: 20580633
[TBL] [Abstract][Full Text] [Related]
6. [Mitochondrial DDS Opens Innovative Pharmaceutics].
Yamada Y
Yakugaku Zasshi; 2016; 136(1):55-62. PubMed ID: 26725668
[TBL] [Abstract][Full Text] [Related]
7. Targeted nucleic acid delivery into tumors: new avenues for cancer therapy.
Wagner E; Kircheis R; Walker GF
Biomed Pharmacother; 2004 Apr; 58(3):152-61. PubMed ID: 15082337
[TBL] [Abstract][Full Text] [Related]
8. [Development of the MITO-porter, a nano device for mitochondrial drug delivery via membrane fusion].
Yamada Y
Yakugaku Zasshi; 2014; 134(11):1143-55. PubMed ID: 25366911
[TBL] [Abstract][Full Text] [Related]
9. Liposomal drug delivery systems--clinical applications.
Goyal P; Goyal K; Vijaya Kumar SG; Singh A; Katare OP; Mishra DN
Acta Pharm; 2005 Mar; 55(1):1-25. PubMed ID: 15907221
[TBL] [Abstract][Full Text] [Related]
10. Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier.
Yamada Y; Harashima H
Mitochondrion; 2013 Sep; 13(5):526-32. PubMed ID: 23000575
[TBL] [Abstract][Full Text] [Related]
11. [Targeting mitochondria: innovation from mitochondrial drug delivery system (DDS) to mitochondrial medicine].
Yamada Y; Harashima H
Yakugaku Zasshi; 2012; 132(10):1111-8. PubMed ID: 23037696
[TBL] [Abstract][Full Text] [Related]
12. Liposomes-mediated delivery of pro-apoptotic therapeutic membrane proteins.
Liguori L; Marques B; Villegas-Mendez A; Rothe R; Lenormand JL
J Control Release; 2008 Mar; 126(3):217-27. PubMed ID: 18234390
[TBL] [Abstract][Full Text] [Related]
13. [Application of novel drug delivery system, fusogenic liposome, for cancer therapy].
Kunisawa J; Mayumi T
Gan To Kagaku Ryoho; 2001 May; 28(5):577-83. PubMed ID: 11383204
[TBL] [Abstract][Full Text] [Related]
14. Strategies for treating mitochondrial disorders: an update.
Scarpelli M; Todeschini A; Rinaldi F; Rota S; Padovani A; Filosto M
Mol Genet Metab; 2014 Dec; 113(4):253-60. PubMed ID: 25458518
[TBL] [Abstract][Full Text] [Related]
15. Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system.
Kogure K; Akita H; Yamada Y; Harashima H
Adv Drug Deliv Rev; 2008 Mar; 60(4-5):559-71. PubMed ID: 18037529
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic approach for diabetic nephropathy using gene delivery of translocase of inner mitochondrial membrane 44 by reducing mitochondrial superoxide production.
Zhang Y; Wada J; Hashimoto I; Eguchi J; Yasuhara A; Kanwar YS; Shikata K; Makino H
J Am Soc Nephrol; 2006 Apr; 17(4):1090-101. PubMed ID: 16510762
[TBL] [Abstract][Full Text] [Related]
17. Targeting the mitochondrial genome via a dual function MITO-Porter: evaluation of mtDNA levels and mitochondrial function.
Yamada Y; Harashima H
Methods Mol Biol; 2015; 1265():123-33. PubMed ID: 25634272
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional enveloped nanodevices (MENDs).
Sato Y; Nakamura T; Yamada Y; Akita H; Harashima H
Adv Genet; 2014; 88():139-204. PubMed ID: 25409606
[TBL] [Abstract][Full Text] [Related]
19. Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: Therapeutic implications.
Bolaños JP; Moro MA; Lizasoain I; Almeida A
Adv Drug Deliv Rev; 2009 Nov; 61(14):1299-315. PubMed ID: 19716390
[TBL] [Abstract][Full Text] [Related]
20. Yeast models of human mitochondrial diseases: from molecular mechanisms to drug screening.
Schwimmer C; Rak M; Lefebvre-Legendre L; Duvezin-Caubet S; Plane G; di Rago JP
Biotechnol J; 2006 Mar; 1(3):270-81. PubMed ID: 16897707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
